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Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating
therapeutic compound in several preclinical cancer models, including acute myeloid leukemia (AML). We and
others have previously reported a vigorous acetylation of the p53 protein by nutlin-treatment. In this study we aimed
to investigate the functional role of this p53 acetylation in nutlin-sensitivity, and further to explore if nutlin-induced
protein acetylation in general could indicate novel targets for the enhancement of nutlin-based therapy.
Results: Nutlin-3 was found to enhance the acetylation of p53 in the human AML cell line MOLM-13 (wild type TP53)
and in TP53 null cells transfected with wild type p53 cDNA. Stable isotope labeling with amino acids in cell culture (SILAC)
in combination with immunoprecipitation using an anti-acetyl-lysine antibody and mass spectrometry analysis identified
increased levels of acetylated Histone H2B, Hsp27 and Hsp90 in MOLM-13 cells after nutlin-treatment, accompanied
by downregulation of total levels of Hsp27 and Hsp90. Intracellular levels of heat shock proteins Hsp27, Hsp40, Hsp60,
Hsp70 and Hsp90α were correlated to nutlin-sensitivity for primary AML cells (n = 40), and AML patient samples with low
sensitivity to nutlin-3 tended to express higher levels of heat shock proteins than more responsive samples. Combination
therapy of nutlin-3 and Hsp90 inhibitor geldanamycin demonstrated synergistic induction of apoptosis in AML cell lines
and primary AML cells. Finally, TP53 null cells transfected with a p53 acetylation defective mutant demonstrated decreased
heat shock protein acetylation and sensitivity to nutlin-3 compared to wild type p53 expressing cells.
Conclusions: Altogether, our results demonstrate that nutlin-3 induces acetylation of p53, histones and heat shock
proteins, and indicate that p53 acetylation status and the levels of heat shock proteins may participate in modulation of
nutlin-3 sensitivity in AML.
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Acute myeloid leukemia (AML) is a quickly progressive
malignant disease of the myeloid lineage of hematopoietic
cells, where overall three-year survival is below 20% for
patients above 65 years [1]. As elderly patients do not tol-
erate the intensive chemotherapy and stem cell transplant-
ation of current treatment regimes [2], the development of
less toxic and more specific targeted therapy is necessary.* Correspondence: bjorn.gjertsen@med.uib.no
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unless otherwise stated.Small-molecule MDM2 inhibitors like nutlin-3 have
emerged as a potent and promising treatment option for
cancers harboring wild type TP53, including AML [3-5],
and the oral formulation of nutlin-3, RG7112, has com-
pleted the first early phase clinical trials for both solid can-
cers and hematological malignancies [6-8]. Intriguingly,
these small-molecule p53 activators have demonstrated
selective toxicity for cancer cells versus normal cells [4,9],
and may also induce reversible cell cycle arrest of normal
cells to protect them from adverse effects of conventional
chemotherapy [10].
While nutlin-3 initially was thought to exert its anti-
cancer activity specifically through inhibition of thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dual-targeting and p53 independent effects of nutlin-3
[11-13]. The efficacy of nutlin-3 and other MDM2 in-
hibitors in hematological malignancies seems however
largely to depend on the expression and activation of
wild type p53 [4,9,14,15]. In addition to TP53 mutational
status, several other molecular mechanisms have been
shown to affect the sensitivity to MDM2 targeted ther-
apy, including FLT3 and NPM1 mutational status
[15-17], E2F-1 transcriptional activity [18], overexpres-
sion of MDMX [19], and MDM2 levels [4,9]. The ob-
served resistance to nutlin-3 in cohorts of AML patients
could be explained by the extensive heterogeneity and
range of molecular abnormalities of the disease [2,4].
For instance, aberrant recruitment of histone deacety-
lases (HDACs) and overexpression of heat shock pro-
teins (Hsps) have been shown to be involved in the
molecular pathogenesis and therapy response of AML
[20,21], and could therefore be considered as potential
therapeutic targets to combine with MDM2 inhibition.
Inhibitors of HDACs and Hsp90 have been found to
enhance p53 acetylation and inhibit MDMX, and syner-
gize with nutlin-3 to induce p53-mediated apoptosis
[22-24]. The direct effect of nutlin-3 on regulation of
histones and heat shock proteins has however not been
determined.
In this study, we aimed to investigate mechanisms
underlying the anti-leukemic activity of nutlin-3. We
examined the functional role of p53 acetylation in
nutlin-sensitivity, and hypothesized that nutlin-induced
acetylation of other proteins than p53 would be of im-
portance for the anti-leukemic effect of nutlin-3. Com-
bining immunoprecipitation of acetylated proteins with
quantitative proteomics, we identified novel targets of
nutlin-induced acetylation, and investigated their partici-
pation in the nutlin-mediated response in AML cell lines
and primary AML cells.
Results
Nutlin-3 enhances p53 acetylation independently of total
levels of p53
While nutlin-3 previously has been shown to enhance
the acetylation of p53 [22,23], it is not clear whether this
is only a consequence of the increase in total levels of
p53. The human AML cell line MOLM-13 (TP53 wild
type) treated with nutlin-3 at increasing time points
demonstrated increased levels of p53, MDM2, p21 and
acetylated p53 (Lys382), while the induction of phos-
phorylated p53 (Ser15 and Ser20) was diminishable
(Figure 1A). To investigate if nutlin-3 could induce
acetylation of p53 independent of a substantial increase
in total p53, we transfected the human osteosarcoma
cell line SAOS-2 (TP53 null) with a cDNA construct
of p53 and treated the cells with nutlin-3. The resultsdemonstrated a higher increase in acetylated p53 (Lys382)
compared to total levels of p53 after nutlin-treatment
(Figure 1B). Similarly, the human lung cancer cell line
H1299 (TP53 null) transfected with p53 and treated with
nutlin-3, followed by immunoprecipitation with an anti-
acetyl-lysine antibody, demonstrated a high increase in
levels of acetylated p53 after nutlin-treatment, and only a
small increase in total levels of p53 (Figure 1C).
Nutlin-3 enhances the acetylation of histone H2B and
heat shock proteins Hsp27 and Hsp90
Based on the critical role of acetylation in nutlin-
induced p53 activation, we wanted to examine if nutlin-
3 could enhance the acetylation of other proteins than
p53. We used stable isotope labeling with amino acids
in cell culture (SILAC) [25] in combination with immu-
noprecipitation of acetylated proteins and mass spec-
trometry analysis to determine alterations in acetylated
proteins after nutlin-treatment in MOLM-13 cells
(for work flow and experimental details, see Figure 2A).
Only proteins with two ore more peptides that were
either two-fold up- or downregulated were considered
significant. From 141 proteins identified with two or
more peptides, 6 proteins were significantly downregu-
lated and 3 proteins were significantly upregulated in re-
sponse to nutlin-3 (see Additional file 1: Table S1 text;
Additional file 2: Table S1). MDM2 is involved in the
regulation of different acetyltransferases and histone
deacetylases, and may interact with and promote ubiqui-
tination and deacetylation of other proteins than p53
[26,27]. As nutlin-3 may inhibit interactions between
MDM2 and other proteins than p53 [11,28], we hypoth-
esized that nutlin-induced disruption between MDM2
and various proteins would prevent their ubiquitination
and promote their acetylation. Hence, we chose to limit
our study to acetylated proteins that were upregulated in
response to nutlin-treatment.
Histone H2B and Hsp27 were among the acetylated
proteins that were more than two-fold up regulated
by nutlin-3 (Table 1) (for example of spectrum, see
Figure 2B). While MDM2 has been shown to mediate
ubiquitination and deacetylation of histones, leading to
transcriptional repression [27], heat shock proteins like
Hsp27 and Hsp90 may interact with both MDM2 and
p53, and promote MDM2 mediated ubiquitination of
p53 [29-31]. Thus, we found it interesting that nutlin-3
could have an effect on regulation of these proteins, and
they were selected for validation in Western blots and
further analysis. Western blots of total lysates from the
SILAC experiment demonstrated upregulation of p53,
MDM2, Histone H2B, acetylated Histone H2B (Lys120)
and acetylated Hsp90 (Lys294), and downregulation of
total levels of Hsp27 and Hsp90 after nutlin-treatment
(Figure 3A). Increased levels of acetylated Hsp27 and
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Figure 1 Nutlin-induced acetylation of p53. (A) MOLM-13 cells were treated with 6 μM nutlin-3 for 0, 2, 4, 6 and 8 hours. Cells subjected to
irradiation (IR) (25 Gy, 2 hours incubation) were included as a positive control, while cells treated with DMSO for 8 hours was used as a negative
control. Western blotting was performed using antibodies against p53, acetylated p53 (Lys382), phoshorylated p53 (Ser15), phosphorylated p53
(Ser20), MDM2 and p21. Actin was used as loading control. (B, C) SAOS-2 and H1299 cells were transiently transfected with cDNA of p53 and
treated with DMSO (control) or 6 μM nutlin-3 for 4 or 6 hours. For SAOS-2 cells, Western blotting was performed using antibodies against p53,
acetylated p53 (Lys382) and actin. For H1299 cells, immunoprecipitation was performed using an anti-acetyl-lysine antibody, followed by Western
blots of p53. Also Western blots of p53 and actin from total lysate used in the immunoprecipitation are shown. Bands were quantified using
region of interest imaging analysis, and values are given as fold induction of control relative to actin.
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by immunoprecipitation with an anti-acetyl-lysine anti-
body in MOLM-13 treated with nutlin-3 (Figure 3B).
Decreased total levels of Hsp27 and Hsp90 after nutlin-
treatment were further validated by flow cytometry
(Figure 3C).Intracellular levels of heat shock proteins and sensitivity
to nutlin-3 in primary AML cells
To investigate if levels of different heat shock proteins
could affect sensitivity to nutlin-3, intracellular protein
levels of Hsp27 (phospho-Ser82), Hsp27 (phospho-Ser15),
Hsp40, Hsp60, Hsp70 and Hsp90α were quantified in
MOLM-13
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Figure 2 (See legend on next page.)
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Figure 2 Nutlin-induced modulation of acetylated proteins in the AML cell line MOLM-13. (A) MOLM-13 cells were subjected to stable
isotope labeling with amino acids in cell culture (SILAC). Cells were labeled with either light (L-Lysine-2HCl, L-Arginine-HCl) or heavy (13C6 L-Lysine-2HCl,
13C6
15 N4 L-Arginine-HCl) isotopes of amino acids and treated with DMSO (control) or 6 μM nutlin-3, respectively, for 6 hours. Cells were harvested and
lysed, and lysates were mixed at a ratio of 1:1 (5 mg protein of each). The lysate was precleared with uMACs protein G Microbeads, then precleared with
beads and an unspecific antibody (rabbit IgG), before immunoprecipitation of acetylated proteins using an anti-acetyl-lysine antibody and Microbeads.
Proteins were eluted in 95°C SDS loading buffer and subjected to one-dimensional gel electrophoresis (SDS-PAGE) and staining with Coomassie Blue.
Bands were excised and peptides generated by trypsination. Peptides were separated and fragmented using LC-MS/MS (LC-LTQ-Orbitrap) and protein
ID’s and H/L ratios were obtained using MaxQuant and Perseus software. (B) Representative MS/MS spectrum of peptides derived from Histone H2B.
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http://www.molecular-cancer.com/content/13/1/116primary AML cells (n = 40) using an Hsp/Chaperone
8-plex MultiBead kit and flow cytometric analysis, while
sensitivity to nutlin-3 was determined in 3H-thymidine in-
corporation assay (Figure 4A) (for AML patient character-
istics, see Additional file 3). Pearson correlation analysis
between nutlin-sensitivity and levels of the different heat
shock proteins revealed no significant correlations (data
not shown). However, when patient samples were divided
into the 10 most sensitive (0 - 53% viability of control) and
10 least sensitive (95 - above 100% viability of control) to
nutlin-3, the least sensitive patient samples showed a trend
towards higher expression levels of most heat shock pro-
teins, although the differences in median values were not
significant (median values for sensitive versus non-sensitive
samples for Hsp27(pSer82): 7.9/7.8 u/ml; Hsp27(pSer15):
5.8/6.1 u/ml; Hsp90 alpha: 10.8/12.0 ng/ml; Hsp40:
14.6/21.9 ng/ml; Hsp70: 42.9/58.7 ng/ml; Hsp60: 262.1/
245.1 ng/ml) (Figure 4B) (for AML patient characteristics,
see Additional file 3). Mean values demonstrated similar
results, but with a stronger tendency to elevated levels of
all heat shock proteins in non-sensitive samples, although
differences were not statistically significant (Figure 4B). In
this data set, patient samples with both wild type and mu-
tated TP53 were included. Given the fact that samples with
mutated TP53 could respond differently to nutlin-3 than
those with wild type TP53, we also performed analyses on
the patient set including only patient samples with con-
firmed wild type TP53 (n = 31). Also for this set of samples,
there were no significant correlations between nutlin-
sensitivity and levels of the different heat shock proteins,
but a tendency to elevated levels of all heat shock proteins
(both median and mean values) in the least sensitive sam-
ples, although there were no significant differences for the
10 most sensitive versus the 10 least sensitive for this pa-
tient set either (Figure S1) [Additional file 4].Table 1 Acetylated proteins more than two-fold up regulated
Accession number Protein IDs Name Number of
P04792 IPI00025512 Hsp27/HSPB1 2
B4DR52 IPI00646240 Histone H2B 2
Q13765 IPI00797126 Alpha-NAC 4
Abbreviations: Alpha-NAC Nascent polypeptide-associated complex subunit alpha, H
between proteins abundance in cells labeled with heavy isotopes compared to cell
in cell culture.Inhibition of Hsp90 sensitizes AML cells to nutlin-induced
apoptosis
As nutlin-3 was found to acetylate and inhibit heat
shock proteins, we investigated their functional role
in nutlin-sensitivity. Hsp90 plays a central role in
leukemogenesis, and preclinical and preliminary clinical
data indicate beneficial effects of Hsp90 inhibitors in the
treatment of AML [21,32]. Moreover, both nutlin-3 and
hsp90 inhibitors are shown to activate p53 [33], and in-
hibition of Hsp90 has been shown to antagonize MDMX
and synergize with nutlin-3 to induce p53-mediated
apoptosis in solid tumors [24]. Hence, we used the
Hsp90 inhibitor geldanamycin to determine if Hsp90
inhibition could enhance the anti-leukemic effect of
nutlin-3. MOLM-13 cells treated with nutlin-3, geldana-
mycin or the combination of both, demonstrated in-
creased sensitivity to the combination therapy compared
to either agent alone determined by Annexin-PI viability
assay (**p < 0.01, *p < 0.05) or staining with Hoechst
33342 (Figure 5A). Synergism for the interaction of
nutlin-3 and geldanamycin was calculated using Bliss in-
dependence analysis, in which the fractional response of
a combination of two drugs equals the sum of the two
fractional responses minus their product. From the re-
sponse to each of the drugs alone, the expected response
to the combination was calculated. If there was a posi-
tive difference between the actual and expected re-
sponse, the combination was considered synergistic [34].
Bliss Independence analysis of the data revealed syner-
gistic apoptosis induction with a higher actual response
than expected response for the combinational therapy
for both assays (Figure 5B). The combinational therapy
was also tested in the AML cell lines OCI-AML3 (wild
type TP53, wild type FLT3) and HL60 (deleted TP53), and
in normal peripheral blood lymphocytes, demonstratingby nutlin-3 detected by SILAC-based mass spectrometry
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Figure 3 Validation of nutlin-induced modulation of acetylated proteins in the AML cell line MOLM-13. (A) Western blots of total lysates
from SILAC (stable labeling with amino acids in cell culture) labeled MOLM-13 cells treated with DMSO or 6 μM nutlin-3 for 6 hours using antibodies
against p53, MDM2, Histone H2B, acetylated Histone H2B (Lys120), Hsp27, Hsp90, acetylated Hsp90 (Lys294) and actin. Bands were quantified using
region of interest imaging analysis, and values are given as fold induction of control relative to actin. (B) MOLM-13 cells were treated nutlin-3 as
described above, and immunoprecipitations using anti-acetyl lysine antibody or an unspecific antibody (rabbit IgG) were performed. Western blots
of Hsp27 of the immunoprecipitated proteins and of the total lysates used in immunoprecipitations are shown. (C) Total levels of Hsp90 and Hsp27
in MOLM-13 cells treated with nutlin-3 as described above analyzed by flow cytometry. Results are given as representative flow diagrams and median
fluorescence intensity (MFI) relative to control.
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http://www.molecular-cancer.com/content/13/1/116decreased sensitivity in cells with wild type TP53 and wild
type FLT3 compared to cells with wild type TP53 and mu-
tated FLT3, and no effect in cells with deleted TP53 or in
normal cells in Annexin-PI viability assay (Figure 5C). Pri-
mary AML cells from 16 patients demonstrated various
sensitivity to the combinational treatment in Annexin-PI
viability assay (Figure 5C); 10 out of 16 patients responded
to the treatment, and 9 out of the 10 responsive patient
samples demonstrated synergism, with a higher actual re-
sponse than expected response for the combinational
treatment (Figure 5D) (for AML patient characteristics,
see Additional file 3).
Role of p53 acetylation in nutlin-sensitivity and regulation
of heat shock proteins
In order to examine the functional role of p53 acetyl-
ation in nutlin-sensitivity, we transfected SAOS-2 andH1299 cells with constructs of p53 full length (p53 FL)
and an acetylation defective mutant (p53 6KR; simultan-
eous mutation of lysine residues 370, 372, 373, 381,
382, and 386 to arginine residues) [35]. Nutlin-treatment
demonstrated reduced sensitivity to nutlin-3 in cells
transfected with p53 6KR compared to cells transfected
with p53 FL in WST-1 viability/proliferations assay for
both cell lines (***p < 0.001, **p < 0.01) (Figure 6A). To
investigate the role of p53 and p53 acetylation in nutlin-
induced modulation of heat shock proteins, we trans-
fected H1299 cells with empty vector, p53 FL and p53
6KR as described above and treated the cells with
nutlin-3, followed by Western blot analysis of p53,
MDM2, acetylated p53 (Lys382), Hsp27, Hsp90 and
acetylated Hsp90 (Lys294) (Figure 6B). The results dem-
onstrated nutlin-induced increase of Hsp27, Hsp90 and
acetylated Hsp90 in cells without p53, downregulation of
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Figure 4 Intracellular heat shock protein levels and sensitivity to nutlin-3 in primary AML cells. (A) Sensitivity to nutlin-3 (10 μM, 24 hours)
in 40 primary AML samples was determined by 3H-thymidine incorporation assay, and samples were analyzed in triplicates. Samples with TP53
mutations are marked with *. Intracellular levels of heat shock proteins Hsp27 (phospho-Ser82), Hsp27 (phospho-Ser15), Hsp40, Hsp60, Hsp70 and
Hsp90α for all samples were determined using Hsp/Chaperone 8-plex MultiBead kit and flow cytrometric analysis. Samples were analyzed in
duplicates. (B) Median values of heat shock protein levels were determined for the patient samples that were sensitive (10 most sensitive ranging
from 18-53% viability of control) and non-sensitive (10 least sensitive ranging from 95-above 100% viability of control) to nutlin-3, and are shown
in the figure together with values for individual patient samples. Samples with TP53 mutations are indicated. Mean values are given below. For
Hsp27 (phospho-Ser82) and Hsp27 (phospho-Ser15) levels are given as u/ml; for Hsp40, Hsp60, Hsp70 and Hsp90α levels are given as ng/ml.
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(See figure on previous page.)
Figure 5 Combinational therapy of nutlin-3 and geldanamycin in AML cells lines and primary AML cells. (A) MOLM-13 cells were treated
with DMSO (control), nutlin-3 (5 μM), geldanamycin (0.5 μM) or the combination of nutlin-3 and geldanamycin for 24 hours and analyzed by
Annexin-PI viability assay. Reduction of viability by the combinational treatment was compared to either compound alone (**p < 0.01, *p < 0.05).
Results are from three independent experiments and error bars represent standard error of mean. Viability values determined by staining with
Hoechst 33342 are given below the Annexin-PI data. (B) Synergism calculated by Bliss Independence analysis for results from Figure (A) showing
expected and actual response for the combinational treatment (C) Sensitivity to nutlin-3 (5 μM), geldanamycin (0.5 μM), or the combination of
both for 24 hours in AML cell lines MOLM-13, HL60, OCI-AML3, normal peripheral blood lymphocytes and 16 primary AML samples analyzed by
Annexin-PI and visualized using TMEV microarray software, with corresponding clinical parameters for each of the patients. (D) Bliss Independence
analysis of expected and actual response for the combinational therapy for each of the individual responding AML patient samples analyzed by
Annexin-PI (n = 10).
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in cells with wild type p53, and no changes in heat shock
protein regulation in response to nutlin-3 in cells trans-
fected with p53 6KR. The transfection of p53 6KR itself
did however cause an increase in levels of acetylated
Hsp90 compared to cells transfected with empty vector.
There was no difference in cell viability by the transfec-
tion itself between empty vector and p53 6KR, while
cells transfected with p53 FL demonstrated a small in-
crease in cell viability compared to empty vector and
p53 6KR (data not shown).
Discussion
Small-molecule MDM2 antagonists like nutlin-3 have
demonstrated beneficial effects in cellular and preclinical
models of various cancer types, including AML [5]. This
type of non-genotoxic specific targeted therapy holds
promise for the treatment of AML patient groups lack-
ing satisfactory treatment options due to toxicity and
complications associated with current treatment regimes
[2]. A better understanding of the molecular mecha-
nisms behind the anti-cancer activity of these com-
pounds is however needed for further development of
this type of therapy. The identification of molecular tar-
gets that could affect the sensitivity to the drug may be
of importance for classification of patient groups that
would benefit from the therapy, and for designing com-
binational therapy in order to overcome resistance,
lower doses, and reduce side effects.
It is well established that expression and activation of
p53 is a major determinant in nutlin-induced apoptosis
[3,4,9]. Previous studies have also shown that nutlin-3
enhances the acetylation of p53 in different human can-
cer cell lines [22,23]. Our results confirm the universality
of nutlin-induced p53 acetylation in both AML cell lines
and other human cancer cell lines, and furthermore
demonstrate that the increase in p53 acetylation is inde-
pendent of a simultaneous increase in total p53. The ex-
periments applying a p53 acetylation defective mutant
clearly illustrate that in addition to expression of p53,
the modulation status of p53 is of great importance in
nutlin-sensitivity. However, it should be taken into con-
sideration that this mutant also is resistant to MDM2mediated ubiquitination, resulting in higher expression
levels of this mutant compared to wild type p53. Import-
antly, the p53 6KR mutant shows intact p53 transcrip-
tional activity, but without the inhibitory regulation of
MDM2 [35]. Acetylation of p53 has been shown to be
essential for its activation and regulation of different
processes [36-38], and to play an important role in ther-
apy response [39,40]. Meanwhile, high expression level
of p53 is associated with poor prognosis and resistance
to therapy in AML [41]. The possibility that the high
levels of p53 is a consequence of modifications like
acetylation, and that also p53 acetylation status in pri-
mary AML samples could provide information about
nutlin-sensitivity need to be examined in future experi-
ments. There are several possible explanations regarding
the molecular mechanisms behind nutlin-induced p53
acetylation; Disruption of MDM2-p53 interaction could
prevent MDM2 mediated ubiquitination or deacetylation
of p53 [42,43], or nutlin-3 could prevent MDM2 from
interacting with and inhibiting acetyl transferases im-
portant for p53 acetylation and activity [44,45]. These
and other possible molecular mechanisms need to be
further explored.
In general, protein lysine acetylation has been shown
to play an important role in regulation of cellular func-
tion and cancer cell signaling, also in AML [46,47].
In addition to inhibiting MDM2-p53 interaction and
modulating p53, nutlin-3 may affect several other proteins,
either as a consequence of p53 transcription-dependent
or -independent effects [48], changed interactions be-
tween MDM2 and other proteins than p53 [11,28], or
direct effect of nutlin-3 interaction with other proteins
than MDM2 [12]. Accordingly, we wanted to examine
if nutlin-3 could enhance the acetylation of other pro-
teins than p53. The methodology using SILAC in com-
bination with an anti-acetyl-lysine antibody and mass
spectrometry analysis has previously successfully been
applied to identify and quantify alterations in acetylated
proteins in cells treated with HDAC inhibitors, and
both histones and heat shock proteins were identified
as lysine acetylated [49,50]. The novel observation that
nutlin-3 enhances the acetylation of histones, could add
information regarding the molecular mechanisms behind
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Figure 6 Functional role of p53 acetylation in nutlin-sensitivity. (A) SAOS-2 and H1299 cells were transiently transfected with empty vector,
p53 full length (FL) or the actylation defective mutant p53 6KR and treated with 20 μM nutlin-3 for 24 hours. Cell viability was determined using
the WST-1 viability/proliferation assay (***p < 0.001, **p < 0.01). Results were analyzed in triplicates in tree independent experiments and error bars
represent standard error of mean. Transfections were verified in Western blots with antibodies against p53 and actin. (B) H1299 cells were transiently
transfected with empty vector (EV), p53 full length (FL), or p53 6KR and treated with DMSO or 20 μM nutlin-3 for 6 hours. Western blotting was
performed using antibodies against p53, MDM2, acetylated p53 (Lys382), Hsp27, Hsp90 and acetylated Hsp90 (Lys294) and actin. Bands were quantified
using region of interest imaging analysis, and values are given as fold induction of control (DMSO treated sample for each transfection for EV/p53
FL/p53 6KR) relative to actin.
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While acetylation of histones is important for their
transcriptional activity [20], acetylation of heat shockproteins have been shown to inhibit their chaperone ac-
tivity and promote their export and extracellular location
[51,52]. This could explain the decrease in total levels of
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acetylation of these proteins. The combination of HDAC
and Hsp90 inhibitors has demonstrated synergism in
leukemia, but antagonism in other tumor models [53].
Also the combination of HDAC inhibitors and nutlin-3
has shown contradictory results in different experimen-
tal settings [22,23,54,55]. As for p53, there are several
possible mechanisms behind nutlin-induced acetylation
of histones and heat shock proteins, including alter-
ations in interaction between MDM2, histones and heat
shock proteins or between MDM2 and components in-
volved in regulating the acetylation of these proteins;
further investigations are therefore warranted.
p53 and p53 acetylation seemed to be of importance
for nutlin-mediated regulation of total and acetylated
levels of heat shock proteins (Figure 6B). Nutlin-induced
acetylation of Hsp90 occurred also in cells without p53,
while downregulation of total levels of Hsp90 and Hsp27
was dependent of wild type p53. Previous studies using
another MDM2 inhibitor have also shown downregula-
tion of other heat shock proteins in wild type p53 cancer
cells in response to treatment [56]. Cells transfected with
a p53 acetylation defective mutant demonstrated in-
creased levels of MDM2 and acetylated Hsp90 by the
transfection itself, but no effects on regulation of total or
acetylated heat shock proteins in response to nutlin-
treatment. In future perspectives, it would be interesting
to perform similar experiments with acetylation defect-
ive heat shock protein mutants to investigate the role of
heat shock protein acetylation in nutlin-induced p53
acetylation.
Sensitivity to both MDM2 and Hsp90 inhibitors is in-
fluenced by different molecular mechanisms in AML
[15,17]. As high expression of heat shock proteins has
been associated with poor prognosis and therapy resist-
ance in AML [21,57], and different heat shock proteins
may interact with and inhibit p53 [29,31], we wanted to
examine if total levels of different heat shock proteins in
AML patient samples could affect the sensitivity to
nutlin-3. We did not find any significant correlations be-
tween nutlin-sensitivity and concentration of intracellu-
lar levels of different heat shock proteins in 40 primary
AML samples. However, when the sample cohort was
divided into sensitive and non-sensitive patient samples,
there was a trend towards higher expression of heat
shock proteins in the least sensitive patient samples, al-
though the differences were not significant. Considering
the fact that samples with TP53 mutations may respond
differently to nutlin-3 compared samples with wild type
p53, we also included analyses on the patient set includ-
ing only samples with wild type TP53 (n = 31), with
similar results. The number of patient samples is how-
ever relatively low; a larger number of patient samples
should therefore be included to determine if there aresignificant differences in heat shock protein levels in
nutlin-sensitive versus non-sensitive samples. It would
also be of interest to correlate levels of acetylated heat
shock proteins and levels of induction of acetylated heat
shock proteins in response to nutlin-3 with nutlin-
sensitivity in primary AML samples.
To examine the functional effect of heat shock protein
inhibition on nutlin-sensitivity, we chose to combine
nutlin-3 with the Hsp90 inhibitor geldanamycin. The
combination of nutlin-3 with Hsp90 inhibitors has previ-
ously demonstrated synergism in solid tumors [24],
while nutlin-3 and geldamamycin exhibited various
effects in classical Hodgkin’s lymphoma depending on
TP53 mutational status [58]. Determination of drug
interaction by Bliss independence analysis assumes that
the two drugs act through independent mechanisms
[34]; nutlin-3 acts as an MDM2 inhibitor, and geldana-
mycin binds to and inhibits Hsp90 (although the may
converge on the same pathway and indirectly affect the
same down stream targets). Based on Bliss independence
analysis with observed higher actual than expected re-
sponse for both MOLM-13 cells and 9 out of 10 respon-
sive primary AML samples, we propose that nutlin-3
and geldanamycin would kill cells independently of each
other in a synergistic manner. Possible mechanisms may
include enhanced Hsp90 inhibition and p53 activation
[33]. As Hsp90 has a wide range of client proteins,
additional molecular mechanisms behind the observed
synergism behind nutlin-3 and Hsp90 inhibitors have
been proposed [24]. To eliminate potential off-target
effects of geldanamycin, the use of short hairpin RNAs
(shRNAs) for stable and specific knockdown of Hsp90 in
combination with nutlin-3 could be an option in future
experiments. Inhibition of Hsp90 has been shown to in-
duce Hsp27, possibly contributing to antagonizing the
anticancer activity of Hsp90 inhibitors [53]. In contrast,
inhibition or knock down of Hsp27 also inhibits Hsp90
[59]. Hence, in future studies, it would be interesting to
combine nutlin-3 with shRNAs or small molecule oligo-
nucleotides against Hsp27.
In our proteomics approach, we restricted the study to
alterations in the lysine acetylome in the whole cell lys-
ate compared to more extensive analysis of the prote-
ome. As no other isolations or fractionations into for
example nuclear and cytoplasmatic fractions were per-
formed, a limitation of this procedure may be that only
the most abundant proteins were detected. Further
investigations could therefore include studying nutlin-
induced acetylation and modulation of other less abun-
dant proteins as well.
Conclusions
In conclusion, our results indicate that acetylation of
p53, histones and heat shock proteins may be a part of
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tivity of nutlin-3. Regulation and function of histones
and heat shock proteins in nutlin-sensitivity need to be
evaluated in a larger number of primary AML cells, as
well as in preclinical and clinical trials.
Methods
Cell lines and primary AML cells
The human AML cell lines MOLM-13 and HL60, and
the human osteosarcoma cell line SAOS-2 and the hu-
man lung cancer cell line H1299 were purchased from
ATCC (American Type Culture Collection, Manassas,
VA, USA), while the human AML cell line OCI-AML3
was purchased from DSMZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, Braunschweig,
Germany). Cell lines were cultured according to manufac-
turer’s procedure. For patient material, all studies were
performed in accordance with the Helsinki declaration
and approved by the regional Ethics Committee (REK
Vest; http://helseforskning.etikkom.no, Norwegian Minis-
try of Education and Research). Samples were collected
after informed consent, and mononuclear cells were
isolated and stored frozen in liquid N2 as previously
described [60]. Normal peripheral blood lymphocytes
were obtained from healthy blood donors (Blodbanken,
Haukeland University Hospital, Bergen, Norway). Primary
AML cells and normal peripheral blood lymphocytes were
cultured in StemSpan SFEM™ (StemCell Technologies
Inc., Vancouver, BC, USA).
Compounds
Nutlin-3 (Cayman Chemical Company, Michigan, USA)
and geldanamycin (Sigma-Aldrich, Inc., St Louis, MO,
USA) were dissolved in DMSO, and stored at −80°C.
When used in cell culture work, the final concentration
of DMSO did not exceed 0.1%.
Western blotting
Western blotting was performed as previously described
[22]. The following antibodies were used; p53 (Bp53-12),
Mdm2 (SMP-14) (Santa Cruz Biotechnology, CA, USA),
Mdm2 (2A10), Mdm2 (IF2), anti-Hsp27 (G3.1) (Calbiochem,
San Diego, CA, USA), p21 (SX118) (BD Biosciences,
San Jose, CA, USA), phospho-p53 (Ser15), phospho-p53
(Ser20), ac-p53 (Lys382) (Cell Signaling Technologies,
Beverly, MA, USA), anti-Histone H2B, anti-Hsp90
(Millipore, Temecula, CA, USA), anti-acetyl-Histone H2B
(Lys120) (Upstate cell signaling solutions, Lake Placid,
NY, USA), anti-acetyl-Hsp90 (Lys294) (Rockland Immu-
nochemicals, Inc., Gilbertsville, PA, USA), secondary horse
radish peroxidase conjugated mouse and rabbit antibody
(Jackson ImmunoResearch, West Grove, PA, USA), actin
(AC-15) (Abcam plc, Cambridge, UK). Bands were quanti-
fied using region of interest analysis on Kodak MolecularImaging Software version 5.0.1 (Carestream Health,
Rochester, NY, USA). Fold induction are given in arbi-
trary units and are defined as protein of interest/actin
following normalization of control.Flow cytometry
Flow cytometric analysis was performed as previously
described [22], using antibodies against Hsp90 α/β (F-8)
PE (Santa Cruz Biotechnology, CA, USA) and Hsp27
(G3.1) PE (Enzo Life Sciences, Farmingdale, NY, USA).Plasmids and transfections
p53 cDNA constructs of p53 FL and p53 6KR were previ-
ously described [35]. Transfections were performed using
X-tremeGENE 9 DNA Transfection Reagent (Roche Diag-
nostics, GmbH, Mannheim, Germany) according to the
manufacturer’s procedure as previously described [61].Cell viability and proliferation assays
Evaluation of apoptosis, viability and proliferation in cell
lines and primary AML cells after drug treatment was
accomplished using Hoechst 33342 (Invitrogen, Carlsbad,
Ca, USA), the viability/proliferation reagent WST-1
(Roche Diagnostics GmbH, Mannheim, Germany), 3H-
thymidine (Amersham International, Amersham, UK) in-
corporation assay, APOTEST-FITC kit (Nexins Research,
Kattendijke, The Netherlands) or Alexa Fluor 488 Annexin
V/ Dead Cell Apoptosis Kit (Molecular Probes, Invitrogen,
Eugene, Oregon, USA) as previously described [22].Immunoprecipitation
Approximately 50 million cells were lysed in Triton® X-100
lysis buffer containing 150 mM NaCl, 50 mM Tris HCl
pH 8.0, 1% Triton® X-100 (Plus one, Pharmacia Biotech,
Uppsala, Sweden), Complete mini Protease inhibitor
cocktail tablet (Roche Diagnostics GmbH, Mannheim,
Germany), 5 mM NaF, 1 mM Na-orthovanadate, 10 mM
nicotinamide and 1 μM TSA, and immunoprecipitation
was carried out using μMACS ProteinG Microbeads
(Miltenyi Biotec, Gladbach, Germany) according to the
manufacturer’s procedure. The cell lysate was pre-cleared
with μMACS Protein G MicroBeads to remove unspecific
binding to the beads followed by a pre-clear using an un-
specific antibody (Chromatographically purified Rabbit
IgG, Invitrogen, Camarillo, CA, USA) and μMACS Protein
G MicroBeads to remove unspecific binding to the immu-
noglobulines, before new μMACS Protein G MicroBeads
and anti-acetyl-lysine antibody (4G12) (Millipore, Billerica,
MA, USA) were added to the pre-cleared lysate for im-
munoprecipitation of acetylated proteins. Proteins were
eluted in 95°C SDS loading buffer and loaded directly on
to a gel for electrophoresis.
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(SILAC), mass spectrometry and analysis of mass
spectrometry data
MOLM-13 cells were grown in SILAC RPMI media with
10% dialyzed FBS, 1% penicillin, 0.1 mg/ml L-Lysine-
2HCL and 0.1 mg/ml mg L-Arginine-HCl, or 0.1 mg/ml
13C6 L-Lysine-2HCl and 0.1 mg/ml mg
13C6
15N4
L-Arginine-HCl (Pierce SILAC Protein Quantification
Kit – RPMI 1640, Thermo Scientific, Pierce Protein Re-
search Products, Rockford, IL, USA) for six passages
[25], and incorporation efficiency was determined by
mass spectrometric analysis. Cell lysates were mixed at a
ratio of 1:1 (5 mg protein of each sample) before immu-
noprecipitation procedures were performed. Eluted pro-
teins from the immunoprecipitation were separated by
one-dimensional gel electrophoresis and stained with
Coomassie Blue (Pharmacia Biotech, Uppsala, Sweden).
The gel was sliced into 13 gel pieces prior to reduction,
alkylation, trypsin digestion and analysis by nano-LC
(Ultimate 3000, Dionex, Sunnyvale, CA, USA) coupled
to an ESI-Orbitrap (LTQ Orbitrap XL, Thermo Scien-
tific, Bremen, Germany) mass spectrometer as previously
described [62]. The peptides were identified and quanti-
fied using the MaxQuant and Perseus software (version
1.2.2.5 and 1.2.0.16) [63] with the following settings: car-
bamidomethyl (C) as fixed modification, and oxidation
(M), acetylation (K) and acetylation (protein N-term) as
variable modifications. FDR was 1%, MS tolerance was
10 ppm and MS/MS tolerance was 0.7 Da. Only proteins
with more than 1 peptide were included in the analysis.
All ratios are given as normalized values and are tested
with Benjamini-Hochberg FDR test (p < 0.05) using sig-
nificance B.
Analysis of intracellular levels of heat shock proteins
Intracellular levels of heat shock proteins Hsp27 (phos-
pho-Ser82), Hsp27 (phospho-Ser15), Hsp40, Hsp60, Hsp70
and Hsp90α were determined using the Hsp/Chaperone
8-plex MultiBead kit (Assay Designs, Inc., Ann Arbor, MI,
USA) according to manufacturer’s instructions as previ-
ously described [17].
Statistical analysis
In cell viability and proliferation assays, triplicates were
analyzed for each sample, and results given as means +/−
standard error of mean. Statistical significance of differ-
ences in averages was determined using a two-tailed
Student’s t-test. For statistical comparison between dif-
ferent patient groups, we used Mann–Whitney U-test.
Correlation analysis was performed using Pearson’s cor-
relation, and synergism was calculated by Bliss Inde-
pendence analysis. For all statistical analysis, p < 0.05
was considered significant. Graphs and calculations
were obtained using GraphPad Prism® 5.0 (GraphPadSoftware, La Jolla, CA, USA). Results from flow cytometric
analysis were visualized using TMEV microarray software
suite version 4.3.01 (Dana-Farber Cancer Institute, Boston,
MA, USA).
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